他汀类药物对急性冠脉综合征患者介入治疗后炎性因子的影响

目的 探讨瑞舒伐他汀对急性冠脉综合征（ACS）患者冠状动脉介入（PCI）治疗术患者血清妊娠相关蛋白-A（PAPP-A）和超敏C-反应蛋白（hs-CRP）的影响.方法 选择2010年8月~2012年9月在我院行冠状动脉介入术的100例急性冠脉综合征患者为研究对象,随机分为2组：瑞舒伐他汀治疗组（瑞舒伐他汀10mg/d,n=51）和对照组（n=49）,分别于药物治疗前、药物治疗后1周及术后12h采集空腹静脉血,测定血清妊娠相关血浆蛋白A（PAPP-A）、超敏C-反应蛋白（hs-CRP）浓度.结果 药物治疗后1周,瑞舒伐他汀治疗组较对照组患者血清PAPP-A和hs-CRP浓度明显降低（P〈0.01）; ACS患者行PCI术后血清PAPP-A和hs-CRP浓度较术前升高;瑞舒伐他汀治疗组PCI术后患者血清PAPP-A和hs-CRP浓度明显低于同期对照组（P〈0.01）.结论 瑞舒伐他汀可降低急性冠脉综合征患者血清PAPP-A和hs-CRP浓度;冠状动脉介入术增加血清PAPP-A和hs-CRP浓度;瑞舒伐他汀可降低冠状动脉介入（PCI）治疗术后患者血清PAPP-A和hs-CRP浓度.

Effect of statins on blood levels of inflammatory cytokines in patients with acute coronary syndrome undergoing percutaneous coronary intervention

Objective To investigate the effect of rosuvastatin on blood levels of hypersensitive C-reactive protein（hsCRP）,pregnancy associated plasma protein-A（PAPP-A） in patients with acute coronary syndrome undergoing percutaneous coronary intervention（PCI）.Methods 100 ACS patients that underwent PCI from Aug 2010 to Sep 2012 in our hospital were randomized into two groups： control group（n=49） and rosuvastatin group（rosuvastatin,10mg/d,n=51）.Serum levels of hsCRP,PAPP-A were measured before and after one week treatment and at 12 hours after the PCI.Results The serum levels of hs-CRP,PAPP-A levels in rosuvastatin group were significantly lower than those in control group after 1 week treatment（P0.01）,PAPP-A and hs-CRP of ACS patients accepted PCI rose higher than before operation,PAPP-A and hs-CRP after PCI in rosuvastatin group were lower than synchronous control group.Conclusion Rosuvastatin can significantly decrease the serum levels of hs-CRP,PAPP-A in patients with ACS.Patients accepted PCI can increase PAPP-A and hs-CRP levels.Rosuvastatin can also significantly decrease the serum levels of hs-CRP and PAPP-A in patients with PCI.